logo
Plus   Neg
Share
Email

Sanofi: FDA To Review Isatuximab As Potential Treatment For RRMM

French pharma major Sanofi (SNYNF,SNY) announced Wednesday that the U.S. Food and Drug Administration has accepted for review the Biologics License Application or BLA for isatuximab to treat patients with relapsed/refractory multiple myeloma or RRMM.

The target action date for the FDA decision is April 30, 2020. Isatuximab is an investigational monoclonal antibody that targets a specific epitope on the CD38 receptor of a plasma cell.

Sanofi said the BLA is based on positive results from ICARIA-MM, an open-label pivotal Phase 3 clinical trial of isatuximab in patients with RRMM.

Isatuximab received orphan designation from both the FDA and the European Medicines Agency for relapsed/refractory multiple myeloma. In the second quarter of 2019, the EMA accepted for review the Marketing Authorization Application.

The company noted that Isatuximab is currently being evaluated in multiple ongoing Phase 3 clinical trials in combination with current standard treatments for people with relapsed/refractory or newly-diagnosed multiple myeloma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Retail giant Walmart Inc. reported Tuesday a profit for the first quarter of fiscal 2022 that declined 31.6 percent from last year, hurt by net losses on equity investments, However, adjusted earnings per share and quarterly revenues topped analysts' expectations. The retailer also raised its guidance for the second quarter and for the full-year 2022. European Medicines Agency or EMA announced that Comirnaty, the COVID-19 vaccine developed by Pfizer and BioNTech, can have more flexible storage conditions, including up to one month in a normal fridge. The proposed change in the approved storage conditions, recommended by EMA's human medicines committee or CHMP, will help in easy handling of the vaccine in vaccination centres across the EU. Kraft Heinz Foods Co. is recalling around 13,504 pounds of a frozen foodservice soup product citing misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The frozen soup product contains milk and eggs, known allergens, which are not declared on the product label.
Follow RTT